Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colm Keane

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Cancers|August 7, 2021
Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour RegressionMartina Proctor, Jazmina L Gonzalez Cruz, Sheena M Daignault-Mill, et al.
Blood|February 17, 2018
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCLFrank Vari, David Arpon, Colm Keane, et al.
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
American Journal of Blood Research|March 21, 2012
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopesDo Nguyen-Van, Colm Keane, Erica Han, et al.
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Oncoimmunology|January 9, 2018
B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activitySara J McKee, Zewen K Tuong, Takumi Kobayashi, et al.
Blood Advances|September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphomaJoseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 4, 2021
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cellsSoi C Law, Thanh Hoang, Kacey O'Rourke, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
British Journal of Haematology|April 8, 2026
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' studyArina Martynchyk, Geoffrey Chong, Richard Khor, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancers|August 7, 2021
Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour RegressionMartina Proctor, Jazmina L Gonzalez Cruz, Sheena M Daignault-Mill, et al.
Blood|February 17, 2018
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCLFrank Vari, David Arpon, Colm Keane, et al.
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
American Journal of Blood Research|March 21, 2012
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopesDo Nguyen-Van, Colm Keane, Erica Han, et al.
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Oncoimmunology|January 9, 2018
B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activitySara J McKee, Zewen K Tuong, Takumi Kobayashi, et al.
Blood Advances|September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphomaJoseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 4, 2021
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cellsSoi C Law, Thanh Hoang, Kacey O'Rourke, et al.
Asia-Pacific Journal of Clinical Oncology|July 7, 2023
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsVanessa F Bonazzi, Lauren G Aoude, Sandra Brosda, et al.
British Journal of Haematology|April 8, 2026
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' studyArina Martynchyk, Geoffrey Chong, Richard Khor, et al.
Pageof 7